Thursday, February 22, 2018
 
 
Company News: Page (1) of 1 - 02/14/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Doctor Evidence collaborated on the underlying systematic review for new guideline published by leading oncology association
Guideline addresses the management of side effects from immune checkpoint inhibitors treatments
(February 14, 2018)

SANTA MONICA, Calif., Feb. 14, 2018 /PRNewswire/ -- Doctor Evidence (DRE), a global health technology and data company, is proud to have performed the systematic review of evidence, through the GROWTH program, in support of a new guideline issued by the American Society of Clinical Oncology, Inc. (ASCO®), the world's leading professional organization representing physicians who care for people with cancer, in collaboration with the National Comprehensive Cancer Network® (NCCN®). The organizations collaborated to develop comprehensive guidelines to help clinicians with optimal strategies for the identification and diagnosis of adverse events associated with immune checkpoint inhibitors and to offer guidance on their safe management.

Doctor Evidence

The Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline published online on February 14, 2018 at 10 AM Eastern in the Journal of Clinical Oncology (JCO) and the ASCO website.



The promise of immune therapies to treat cancers also leads to challenges, including side effects. Immune checkpoint inhibitors, the first of the new immunotherapeutics, block the immune checkpoint proteins, which limit the strength and duration of the immune response. Immune checkpoint inhibitors thereby unleash the body's own immune system to attack tumor cells, thereby increasing its ability to destroy cancer cells and extend lives. Several immune checkpoint modulators have now been approved by the FDA for specific cancer types, primarily advanced melanoma, but also including Hodgkin lymphoma, and lung, liver, kidney, and bladder cancers. Additional indications and development of new immunotherapies exposes more patients to these new treatments as they are prescribed more commonly.

Patients may experience side effects ranging from very mild to quite severe, and potentially fatal reactions. Toxicities of these agents are usually rashes, diarrhea, thyroid hormone reductions, and fatigue. However, they can include inflammation of the lung, intestines, liver or neurologic, renal, or cardiac problems. Because these treatments are relatively new, clinicians are not experienced in recognizing and treating these adverse effects.

"These recommendations are important for physicians' knowledge and clinical management to guide the appropriate use of these new immunotherapeutics," stated Robert Battista, MBA, CEO and co-founder of Doctor Evidence. "We are fortunate we could extend our GROWTH program for scientific collaborations to support the systematic evidence review for these leading oncology societies' guidelines."

ABOUT DOCTOR EVIDENCE:
Doctor Evidence (DRE) is a health technology and consulting company utilizing state-of-the-art solutions that identify, synthesize, and analyze complex clinical research data into fit-to-purpose actionable knowledge. Resulting high quality evidence reviews provide guideline developers, academic researchers, medical providers, manufacturers, payers, and patients with evidence-based information to make timely and educated decisions on recommended treatment protocols, outcomes research, health economics, risk management, market access, reimbursement, value determinations, and burden of illness cost models. These methodologically rigorous reviews and analyses fully comply with accepted international standards to address the needs of patients, providers, and scientists worldwide. To learn more about Doctor Evidence, visit GROWTHevidence.com and drevidence.com.

ASCO® is a registered trademark of the American Society of Clinical Oncology, Inc. Used with permission. ASCO is not a partner or affiliate of Doctor Evidence and does not recommend or endorse any vendor, product, or service.

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/doctor-evidence-collaborated-on-the-underlying-systematic-review-for-new-guideline-published-by-leading-oncology-association-300598781.html

SOURCE Doctor Evidence

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords: Inc.,Cancer,Surgery,Physician,Science,Medical,Cancer,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • SourceLink Partners with MassMedia Health to Provide Medicare Age-In Data to Healthcare Groups
  • Global Mobile Medical Apps Market to Reach $11.22 Billion by 2025, Reports BIS Research
  • U.S. Nebulizer Market Size Worth $435.5 Million By 2025 | CAGR 6.2%: Grand View Research, Inc.
  • Global Cables and Leads for Medical Equipment Industry
  • Pain Management Devices Market USD 5.81 Billion Revenue At 7.2 % CAGR by 2023; Exclusively Available at MarketResearchFuture.com

    Cancer
  • argenx to host conference call & webcast to report fourth quarter business update and full year 2017 financial results on March 1, 2018
  • QCCA Evolves to Become the First National Clinically Integrated Network in Oncology
  • COA: Analysis Shows Virginia Hospitals Benefit From Recent Changes In Medicare Payment
  • 2018 Global Endometriosis Strategic Business Report - Developing Regions Exhibit Immense Growth Potential
  • Cannabics Pharmaceuticals Hires Chief Data Officer to Address Industry Compliance and Utilization/Analytics Application
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines